F. Rojo

F. Rojo, J. Albanell, A. Rovira, 2007, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

mRNA In Situ Hybridization (HistoSonda): A New Diagnostic Tool for HER2-Status in Breast Cancer–A Multicentric Spanish Study

F. Rojo, Javier Alba, R. Rezola, 2012, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

Determination of True ERBB2 Gene Amplification in Breast Cancer by Quantitative PCR Using a Reference and a Novel Control Gene

F. Rojo, J. Madoz-Gúrpide, C. Chamizo, 2016, Applied immunohistochemistry & molecular morphology : AIMM.

Optimal dose of cetuximab (C) given every 2 weeks (q2w): A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of weekly (q1w) and q2w schedules in patients (pts) with metastatic colorectal cancer (mCRC).

J. Baselga, F. Rojo, J. Tabernero, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cyclo-oxygenase type 2 is dysregulated in breast ductal carcinoma in situ and correlates with poor outcome.

F. Rojo, J. De La Torre, S. Ramón y. Cajal, 2010, European journal of obstetrics, gynecology, and reproductive biology.

Biomarker testing strategies in non-small cell lung cancer in the real-world setting: analysis of methods in the Prospective Central Lung Cancer Biomarker Registry (LungPath) from the Spanish Society of Pathology (SEAP)

Javier M. Martín-López, F. Rojo, T. Hernández-Iglesias, 2021, Journal of Clinical Pathology.

Assessment of a New ROS 1 Immunohistochemistry Clone ( SP 384 ) for the Identification of ROS 1 Rearrangements in Non-Small Cell Lung Carcinoma Patients : the ROSING Study Running title : ROS 1 Immnunohistochemistry with clone SP 384

J. Mate, M. Salido, E. Felip, 2019 .

p‐MAPK1 expression associated with poor prognosis in angioimmunoblastic T‐cell lymphoma patients

M. Piris, F. Rojo, Nerea Carvajal, 2017, British journal of haematology.

Detection of breast cancer stem cell gene mutations in circulating free DNA during the evolution of metastases

G. Mills, Jenny C. Chang, F. Rojo, 2019, Breast Cancer Research and Treatment.

FoxA and LIPG endothelial lipase control the uptake of extracellular lipids for breast cancer growth

Xavier Salvatella, Oscar Yanes, Maria Vinaixa, 2016, Nature Communications.

The value of sentinel lymph-node biopsy after neoadjuvant therapy: an overview

F. Rojo, A. Lluch, X. Bonfill, 2022, Clinical and Translational Oncology.

Hyperphosphorylation of PP2A in colorectal cancer and the potential therapeutic value showed by its forskolin-induced dephosphorylation and activation.

F. Rojo, J. Madoz-Gúrpide, J. García-Foncillas, 2014, Biochimica et biophysica acta.

Validation of microRNA-199b as A Promising Predictor of Outcome and Response to Neoadjuvant Treatment in Locally Advanced Rectal Cancer Patients

F. Rojo, J. Madoz-Gúrpide, S. Zazo, 2021, Cancers.

Low MicroRNA-19b Expression Shows a Promising Clinical Impact in Locally Advanced Rectal Cancer

F. Rojo, J. Madoz-Gúrpide, S. Zazo, 2021, Cancers.

DEK is a potential marker for aggressive phenotype and irinotecan-based therapy response in metastatic colorectal cancer

A. Cebrián, F. Rojo, M. Soengas, 2014, BMC Cancer.

Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer

P. Jares, F. Rojo, M. Rubini, 2017, British Journal of Cancer.

Prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancer

F. Rojo, J. Tabernero, J. García-Foncillas, 2018, British Journal of Cancer.

Consensus of the Spanish Society of Medical Oncology (SEOM) and Spanish Society of Pathology (SEAP) for HER2 testing in gastric carcinoma

F. López-Ríos, F. Rojo, J. Palacios, 2011, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer

Andrew H. Beck, Jacqueline A. Hall, Sarah N. Dudgeon, 2020, npj Breast Cancer.

High Proliferation Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Early Breast Cancer

F. Rojo, J. Albanell, A. Ruíz, 2016, The oncologist.

A phase I study of AEE788, a multitargeted inhibitor of ErbB and VEGF receptor family tyrosine kinases, to determine safety, PK and PD in patients (pts) with advanced colorectal cancer (CRC) and liver metastases

C. Takimoto, F. Rojo, J. Abbruzzese, 2007 .

Methylation status of IGFBP-3 as a useful clinical tool for deciding on a concomitant radiotherapy

F. Rojo, J. Albanell, A. Rovira, 2014, Epigenetics.

Active angiogenesis in metastatic renal cell carcinoma predicts clinical benefit to sunitinib-based therapy

F. Rojo, J. Madoz-Gúrpide, S. Zazo, 2014, British Journal of Cancer.

Dynamic clonal remodelling in breast cancer metastases is associated with subtype conversion.

G. Mills, A. Gonzalez-Perez, F. Meric-Bernstam, 2019, European journal of cancer.

Vitamin D receptor expression and associated gene signature in tumour stromal fibroblasts predict clinical outcome in colorectal cancer

D. Pisano, F. Rojo, G. Gómez-López, 2016, Gut.

F. Rojo, S. Y. Cajal, A. Carnero, 2006, Oncology reports.

Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial.

Roy S Herbst, W. Hong, J. Baselga, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase II Pharmacodynamic Study of Erlotinib in Patients with Advanced Non–Small Cell Lung Cancer Previously Treated with Platinum-Based Chemotherapy

J. Möcks, E. Felip, S. Cedrés, 2008, Clinical Cancer Research.

Deep diving in the PACIFIC: Practical issues in stage III non-small cell lung cancer to avoid shipwreck

M. Juan, F. Rojo, X. Mielgo-Rubio, 2020, World journal of clinical oncology.

Phase II pharmacodynamic trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients previously treated with platinum-based chemotherapy: FISH results.

J. Möcks, J. Baselga, E. Felip, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Multidisciplinary consensus on optimising the detection of NTRK gene alterations in tumours

F. López-Ríos, F. Rojo, E. de Álava, 2021, Clinical and Translational Oncology.

Caveolin-1 is Markedly Downregulated in Patients with Early-Stage Colorectal Cancer

F. Rojo, J. García-Foncillas, I. Cristóbal, 2017, World Journal of Surgery.

Inhibition of Specific NF-κB Activity Contributes to the Tumor Suppressor Function of 14-3-3σ in Breast Cancer

N. López-Bigas, Alba Jené-Sanz, R. Gomis, 2012, PloS one.

Effect of MAF amplification on treatment outcomes with adjuvant zoledronic acid in early breast cancer: a secondary analysis of the international, open-label, randomised, controlled, phase 3 AZURE (BIG 01/04) trial.

W. Gregory, R. Gomis, F. Rojo, 2017, The Lancet. Oncology.

Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer

F. Rojo, J. Albanell, A. Lluch, 2022, Science advances.

A phase I study of a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody “EMD72000 (Matuzumab)” administered weekly in Japanese patients with advanced solid tumors; safety, PK and PD results of skin biopsies

N. Saijo, F. Rojo, A. Ohtsu, 2005 .

Reduction of cytosolic p27(Kip1) inhibits cancer cell motility, survival, and tumorigenicity.

Frederick Y. Wu, J. Baselga, F. Rojo, 2006, Cancer research.

Inhibition of the Canonical IKK/NFκB Pathway Sensitizes Human Cancer Cells to Doxorubicin

F. Rojo, J. Albanell, P. Gascón, 2007 .

A phase I study with tumor molecular pharmacodynamic (MPD) evaluation of dose and schedule of the oral mTOR-inhibitor Everolimus (RAD001) in patients (pts) with advanced solid tumors

Suzanne F. Jones, J. Baselga, F. Rojo, 2005 .

Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer

Andrew H. Beck, Jacqueline A. Hall, A. Beck, 2020, npj Breast Cancer.

Running title : Different role of Gasdermin B isoforms in pyroptosis . 4 5

F. Rojo, J. Albanell, A. Lluch, 2022 .

TITLE: CIRCULATING IMMUNE BIOMARKERS IN PERIPHERAL BLOOD CORRELATE WITH CLINICAL OUTCOMES IN ADVANCED BREAST CANCER.

F. Rojo, V. Sánchez-Margalet, R. Caballero, 2021 .

Efficacy and safety of dasatinib with trastuzumab and paclitaxel in first line HER2-positive metastatic breast cancer: results from the phase II GEICAM/2010-04 study

F. Rojo, J. Montero, A. Pandiella, 2019, Breast Cancer Research and Treatment.

Correction to: Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology

F. Rojo, J. Albanell, M. Martín, 2018, Clinical and Translational Oncology.

Coexpression of p-IGF-1R and MMP-7 Modulates Panitumumab and Cetuximab Efficacy in RAS Wild-Type Metastatic Colorectal Cancer Patients

F. Rojo, J. Feliu, J. Maurel, 2018, Neoplasia.

Inhibition of the canonical IKK/NF kappa B pathway sensitizes human cancer cells to doxorubicin.

F. Rojo, J. Albanell, P. Gascón, 2007, Cell cycle.

Mutations in the JAK/STAT pathway genes and activation of the pathway, a relevant finding in nodal Peripheral T‐cell lymphoma

M. Piris, F. Rojo, M. Sánchez-Beato, 2018, British journal of haematology.

Relevance of the PP2A Pathway in the Molecular Mechanisms of Chronic Obstructive Pulmonary Disease.

F. Rojo, J. García-Foncillas, I. Cristóbal, 2019, American journal of respiratory cell and molecular biology.

The value of sentinel lymph-node biopsy after neoadjuvant therapy: an overview

F. Rojo, A. Lluch, X. Bonfill, 2022, Clinical and Translational Oncology.

The value of sentinel lymph-node biopsy in women with node-positive breast cancer at diagnosis and node-negative tumour after neoadjuvant therapy: a systematic review

F. Rojo, A. Lluch, X. Bonfill, 2022, Clinical and Translational Oncology.

Pharmacodynamic studies with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839.

J. Baselga, F. Rojo, J. Albanell, 2001, Seminars in oncology.

Phase I study of the humanised anti-EGFR monoclonal antibody matuzumab (EMD 72000) combined with gemcitabine in advanced pancreatic cancer

F. Rojo, W. Schmiegel, T. Südhoff, 2006, British Journal of Cancer.

Comprehensive Approach to Genomic and Immune Profiling: Insights of a Real-World Experience in Gynecological Tumors

F. Rojo, S. Zazo, C. Chamizo, 2022, Diagnostics.

Clinical and economic impact of ‘ROS1-testing’ strategy compared to a ‘no-ROS1-testing’ strategy in advanced NSCLC in Spain

F. Rojo, E. Nadal, L. Cabezón-Gutiérrez, 2021, BMC cancer.

Molecular markers of the mTOR pathway activation in human tumors: A baseline analysis.

J. Baselga, F. Rojo, J. Tabernero, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical Impact of Circulating Tumor RAS and BRAF Mutation Dynamics in Patients With Metastatic Colorectal Cancer Treated With First-Line Chemotherapy Plus Anti-Epidermal Growth Factor Receptor Therapy.

F. Rojo, B. Bellosillo, C. Montagut, 2019, JCO precision oncology.

Prospective evaluation of BRAF, PI3K and PTEN as predictive and prognostic biomarkers in first-line advanced KRAS wild-type colorectal cancer treated with FOLFOX or FOLFIRI plus bi-weekly cetuximab. GEMCAD 10-02

F. Rojo, J. Feliu, M. Cuatrecasas, 2016 .

Phase I study of AEE788, a novel multitargeted inhibitor of ErbB and VEGF receptor family tyrosine kinases: A pharmacokinetic (PK)-pharmacodynamic (PD) study to identify the optimal therapeutic dose regimen

J. Baselga, C. Takimoto, F. Rojo, 2005 .

Potential involvement of protein phosphatase 2A in temsirolimus-mediated resensitization to cetuximab in colon cancer cells

F. Rojo, J. Madoz-Gúrpide, J. García-Foncillas, 2014, Journal of Cancer Research and Clinical Oncology.

Pembrolizumab Plus Gemcitabine in the Subset of Triple-Negative Advanced Breast Cancer Patients in the GEICAM/2015-04 (PANGEA-Breast) Study

F. Rojo, R. Andrés, V. Sánchez-Margalet, 2021, Cancers.

M. Piris, F. Rojo, J. Menárguez, 2016, Haematologica.

GEICAM Guidelines for the Management of Patients with Breast Cancer During the COVID‐19 Pandemic in Spain

F. Rojo, A. Guerrero-Zotano, J. García-Saenz, 2020, The oncologist.

Clinical Value of miR-26b Discriminating Ulcerative Colitis-associated Colorectal Cancer in the Subgroup of Patients with Metastatic Disease.

F. Rojo, J. Madoz-Gúrpide, P. González-Alonso, 2015, Inflammatory bowel diseases.

High TGFbeta-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene.

Alejandra Bruna, J. Mora, J. Baselga, 2007, Cancer cell.

Vitamin D differentially regulates colon stem cells in patient‐derived normal and tumor organoids

F. Real, P. Jung, L. Peso, 2019, The FEBS journal.

Comment on Goldsworthy et al. Haploinsufficiency of the Insulin Receptor in the Presence of a Splice-Site Mutation in Ppp2r2a Results in a Novel Digenic Mouse Model of Type 2 Diabetes. Diabetes 2016;65:1434–1446

F. Rojo, J. Madoz-Gúrpide, J. García-Foncillas, 2016, Diabetes.

Mutational Screening of BRCA1/2 Genes as a Predictive Factor for Therapeutic Response in Epithelial Ovarian Cancer: A Consensus Guide from the Spanish Society of Pathology (SEAP-IAP) and the Spanish Society of Human Genetics (AEGH)

J. Cigudosa, F. Rojo, A. Osorio, 2019, Virchows Archiv.

MicroRNA-19b Plays a Key Role in 5-Fluorouracil Resistance and Predicts Tumor Progression in Locally Advanced Rectal Cancer Patients

F. Rojo, J. Madoz-Gúrpide, S. Zazo, 2022, International journal of molecular sciences.

Abstract P6-08-10: Prospective study of the impact of the Prosigna™ assay on adjuvant clinical decision-making in women with estrogen receptor-positive, HER2-negative, node-negative breast cancer: A GEICAM study

J. Hornberger, F. Rojo, J. Albanell, 2015 .

The RHOA G17V gene mutation occurs frequently in peripheral T-cell lymphoma and is associated with a characteristic molecular signature.

M. Piris, F. Rojo, M. Sánchez-Beato, 2014, Blood.

PD-L1 testing based on SP142 antibody in metastatic triple-negative breast cancer: summary of an expert round-table discussion.

F. Rojo, L. Comerma, V. Peg, 2020, Future oncology.

Vitamin C uncouples the Warburg metabolic switch in KRAS mutant colon cancer

M. Fraga, F. Rojo, S. Zazo, 2016, Oncotarget.

Tumor-Infiltrating Lymphocytes and Immune Response in HER2-Positive Breast Cancer

F. Rojo, J. Madoz-Gúrpide, S. Zazo, 2022, Cancers.

Pembrolizumab in combination with gemcitabine for patients with HER2-negative advanced breast cancer: GEICAM/2015–04 (PANGEA-Breast) study

F. Rojo, M. Ramos, R. Caballero, 2022, BMC Cancer.

Mutual regulation between BCL6 and a specific set of miRNAs controls TFH phenotype in peripheral T‐cell lymphoma

M. Piris, F. Rojo, C. Chamizo, 2018, British journal of haematology.

Cytogenetic characterization of NCI-H69 and NCI-H69AR small cell lung cancer cell lines by spectral karyotyping.

S. Serrano, F. Solé, M. Salido, 2009, Cancer genetics and cytogenetics.

Potential therapeutic value of miR‐425‐5p in metastatic colorectal cancer

F. Rojo, J. Madoz-Gúrpide, J. García-Foncillas, 2016, Journal of cellular and molecular medicine.

Excision repair cross-complementing 1 (ERCC1) and survival in advanced bladder cancer: Confirmatory results using immunohistochemistry.

J. Lloreta, J. J. de la Cruz, J. Carles, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I Pharmacokinetic/Pharmacodynamic Study of EKB-569, an Irreversible Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Combination with Irinotecan, 5-Fluorouracil, and Leucovorin (FOLFIRI) in First-Line Treatment of Patients with Metastatic Colorectal Cancer

Susan Quinn, Gunnar Folprecht, Josep Tabernero, 2008, Clinical Cancer Research.

Practical considerations for optimising homologous recombination repair mutation testing in patients with metastatic prostate cancer

A. Stenzinger, R. Eeles, A. Wyatt, 2021, The journal of pathology. Clinical research.

Targeted therapies in breast cancer.

F. Rojo, J. Albanell, A. Rovira, 2008, Seminars in diagnostic pathology.

Nuclear PARP-1 protein overexpression is associated with poor overall survival in early breast cancer.

S. Serrano, F. Rojo, J. Yélamos, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer.

C. Perou, R. Gomis, V. Adamo, 2017, Cancer research.

Regulatory and Functional Connection of Microphthalmia-Associated Transcription Factor and Anti-Metastatic Pigment Epithelium Derived Factor in Melanoma1

F. Rojo, C. Bertolotto, S. Zazo, 2014, Neoplasia.

Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors.

Suzanne F. Jones, F. J. Ramos, J. Baselga, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Targeted Therapy Modulates the Secretome of Cancer-Associated Fibroblasts to Induce Resistance in HER2-Positive Breast Cancer

F. Rojo, J. Albanell, J. Madoz-Gúrpide, 2021, International Journal of Molecular Sciences.

Preclinical and Clinical Characterization of Fibroblast-derived Neuregulin-1 on Trastuzumab and Pertuzumab Activity in HER2-positive Breast Cancer

B. Lloveras, F. Rojo, J. Albanell, 2021, Clinical Cancer Research.

Targeting stromal remodeling and cancer stem cell plasticity overcomes chemoresistance in triple negative breast cancer

F. Rojo, S. O'toole, P. Timpson, 2018, Nature Communications.

Generation, characterization, and maintenance of trastuzumab-resistant HER2+ breast cancer cell lines.

F. Rojo, J. Albanell, A. Lluch, 2016, American journal of cancer research.

Deficiency in p53 is required for doxorubicin induced transcriptional activation of NF-κB target genes in human breast cancer

F. Rojo, J. Albanell, L. Espinosa, 2013, Oncotarget.

Pharmacodynamic studies of gefitinib in tumor biopsy specimens from patients with advanced gastric carcinoma.

J. Baselga, E. Van Cutsem, F. Rojo, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Activation of MET pathway predicts poor outcome to cetuximab in patients with recurrent or metastatic head and neck cancer

F. Rojo, J. Madoz-Gúrpide, S. Zazo, 2015, Journal of Translational Medicine.

Poly (ADP-ribose) polymerase inhibition enhances trastuzumab antitumour activity in HER2 overexpressing breast cancer.

F. Rojo, J. Yélamos, J. Albanell, 2014, European journal of cancer.

The Novel Oral mTORC1/2 Inhibitor TAK-228 Reverses Trastuzumab Resistance in HER2-Positive Breast Cancer Models

F. Rojo, J. Albanell, J. Madoz-Gúrpide, 2021, Cancers.

Association of p27 and Cyclin D1 Expression and Benefit from Adjuvant Trastuzumab Treatment in HER2-Positive Early Breast Cancer: A TransHERA Study

M. Dowsett, R. Gelber, D. Larsimont, 2018, Clinical Cancer Research.

The role of miR-26a and miR-30b in HER2+ breast cancer trastuzumab resistance and regulation of the CCNE2 gene

F. Rojo, J. Albanell, A. Lluch, 2017, Scientific Reports.

HER2 as a target in invasive urothelial carcinoma

M. Loda, M. Salido, E. Gallardo, 2015, Cancer medicine.

Multicenter Evaluation of the Idylla NRAS-BRAF Mutation Test in Metastatic Colorectal Cancer.

J. L. Costa, F. Rojo, R. Yacobi, 2018, The Journal of molecular diagnostics : JMD.

TACE is required for the activation of the EGFR by TGF‐α in tumors

J. Baselga, F. Rojo, J. Albanell, 2003 .

Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.

J. Baselga, F. Rojo, J. Arribas, 2007, Journal of the National Cancer Institute.

Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer

C. Nadal, F. Rojo, R. López-López, 2019, Scientific Reports.

Prospective study of the impact of the Prosigna assay on adjuvant clinical decision-making in unselected patients with estrogen receptor positive, human epidermal growth factor receptor negative, node negative early-stage breast cancer

S. Ferree, J. Hornberger, F. Rojo, 2015, Current medical research and opinion.

Non-canonical NF-κB pathway activation predicts outcome in borderline oestrogen receptor positive breast carcinoma

A. Gonzalez-Perez, F. Rojo, J. Albanell, 2016, British Journal of Cancer.

NH2-terminal Truncated HER-2 Protein but not Full-Length Receptor Is Associated with Nodal Metastasis in Human Breast Cancer

J. Garcia-conde, J. Baselga, F. Rojo, 2002 .

NH(2)-terminal truncated HER-2 protein but not full-length receptor is associated with nodal metastasis in human breast cancer.

J. Garcia-conde, J. Baselga, F. Rojo, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Dissecting the therapeutic implications of the complex SMAD4 regulatory network in metastatic colorectal cancer.

F. Rojo, J. García-Foncillas, I. Cristóbal, 2018, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Genetic changes in small cell lung carcinoma

F. Rojo, J. Albanell, A. Rovira, 2008, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

4E-Binding Protein 1, A Cell Signaling Hallmark in Breast Cancer that Correlates with Pathologic Grade and Prognosis

J. Baselga, F. Rojo, S. Y. Cajal, 2007, Clinical Cancer Research.

Molecular diagnosis in non-small-cell lung cancer: expert opinion on ALK and ROS1 testing

M. Salido, F. Rojo, E. de Álava, 2021, Journal of Clinical Pathology.

Novel Oral mTORC1/2 Inhibitor TAK-228 Has Synergistic Antitumor Effects When Combined with Paclitaxel or PI3Kα Inhibitor TAK-117 in Preclinical Bladder Cancer Models

F. Rojo, J. Albanell, O. Arpí, 2019, Molecular Cancer Research.

A SNAIL1–SMAD3/4 transcriptional repressor complex promotes TGF-β mediated epithelial–mesenchymal transition

R. Crystal, F. Rojo, K. Pietras, 2009, Nature Cell Biology.

Level of HER2 gene amplification predicts response and overall survival in HER2-positive advanced gastric cancer treated with trastuzumab.

M. Hidalgo, F. López-Ríos, F. Rojo, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase IB study of the mTOR inhibitor ridaforolimus with capecitabine.

F. Rojo, J. Albanell, F. Haluska, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase Ib study of weekly mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) with weekly paclitaxel.

F. Rojo, J. Albanell, F. Haluska, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

MicroRNA-33b Suppresses Epithelial–Mesenchymal Transition Repressing the MYC–EZH2 Pathway in HER2+ Breast Carcinoma

F. Rojo, J. Albanell, A. Lluch, 2020, Frontiers in Oncology.

MicroRNA-199b Downregulation Confers Resistance to 5-Fluorouracil Treatment and Predicts Poor Outcome and Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer Patients

F. Rojo, J. Madoz-Gúrpide, S. Zazo, 2020, Cancers.

mTOR signaling in human cancer

F. Rojo, J. Albanell, A. Rovira, 2007 .

Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments.

J. Baselga, R. Nicholson, F. Rojo, 2001, Cancer research.

Cross Talk between Wnt/β-Catenin and CIP2A/Plk1 Signaling in Prostate Cancer: Promising Therapeutic Implications

F. Rojo, J. Madoz-Gúrpide, J. García-Foncillas, 2016, Molecular and Cellular Biology.

4E-binding protein 1: a key molecular "funnel factor" in human cancer with clinical implications.

J. Baselga, F. Rojo, S. Ramón y. Cajal, 2007, Cancer research.

Phosphorylated 4E binding protein 1: A hallmark of cell signaling that correlates with survival in ovarian cancer

J. Baselga, F. Rojo, S. Ramón y. Cajal, 2006, Cancer.

Mitogen-Activated Protein Kinase Phosphatase-1 in Human Breast Cancer Independently Predicts Prognosis and Is Repressed by Doxorubicin

Beatriz Bellosillo, Ignasi Tusquets, Rosario Perona, 2009, Clinical Cancer Research.

MET phosphorylation predicts poor outcome in small cell lung carcinoma and its inhibition blocks HGF-induced effects in MET mutant cell lines

S. Serrano, M. Salido, F. Hirsch, 2011, British Journal of Cancer.

Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.

A. Harris, J. Baselga, M. Ranson, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

C-MET as a new therapeutic target for the development of novel anticancer drugs

F. Rojo, J. Albanell, M. Arumí-Uría, 2010, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

Targeting stromal remodeling and cancer stem cell plasticity overcomes chemoresistance in triple negative breast cancer

F. Rojo, S. O'toole, P. Timpson, 2017, Nature Communications.

Combined Epidermal Growth Factor Receptor Targeting with the Tyrosine Kinase Inhibitor Gefitinib (ZD1839) and the Monoclonal Antibody Cetuximab (IMC-C225)

J. Baselga, F. Rojo, J. Tabernero, 2004, Clinical Cancer Research.

Pharmacological Approaches in an Experimental Model of Non-Small Cell Lung Cancer: Effects on Tumor Biology.

F. Rojo, E. Barreiro, A. Urtreger, 2016, Current pharmaceutical design.

Colon cancer modulation by a diabetic environment: A single institutional experience

F. Rojo, A. Sanz, A. Ortiz, 2017, PloS one.

The Role of MicroRNAs in Hepatoblastoma Tumors

F. Rojo, J. García-Foncillas, C. Caramés, 2019, Cancers.

DUSP1/MKP1 promotes angiogenesis, invasion and metastasis in non-small-cell lung cancer

A Rovira, F. Rojo, J. Albanell, 2011, Oncogene.

Are ER+PR+ and ER+PR- breast tumors genetically different? A CGH array study.

S. Serrano, J. Cigudosa, F. Solé, 2012, Cancer genetics.

Snail1-expressing fibroblasts in the tumor microenvironment display mechanical properties that support metastasis.

D. Navajas, F. Rojo, J. Albanell, 2015, Cancer research.

The complex life of DICKKOPF-1 in cancer cells

F. Rojo, A. Muñoz, J. González-Sancho, 2015 .

International real-world study of DLL3 expression in patients with small cell lung cancer.

F. Rojo, F. Penault-Llorca, P. Pauwels, 2020, Lung cancer.

Mitogen-activated protein kinase phosphatase-1 (MKP-1) impairs the response to anti-epidermal growth factor receptor (EGFR) antibody cetuximab in metastatic colorectal cancer patients

S. Serrano, F. Rojo, J. Albanell, 2010, British Journal of Cancer.

Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of a phase I dose-escalation study.

F. J. Ramos, J. Baselga, F. Rojo, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical and economic impact of current ALK rearrangement testing in Spain compared with a hypothetical no-testing scenario

F. Rojo, J. García, E. Nadal, 2021, BMC cancer.

Nuclear NF-κB/p65 expression and response to neoadjuvant chemotherapy in breast cancer

Robin L. Jones, M. Dowsett, J. Reis-Filho, 2010, Journal of Clinical Pathology.

Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition.

J. Baselga, R. Nicholson, R. Herbst, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Potential anti-tumor effects of FTY720 associated with PP2A activation: a brief review

F. Rojo, J. Madoz-Gúrpide, P. González-Alonso, 2016, Current medical research and opinion.

Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

F. Rojo, E. de Álava, J. Rodríguez-Peralto, 2019, Clinical and Translational Oncology.

Immune checkpoint inhibitor treatment in patients with oncogene-addicted non-small cell lung cancer (NSCLC): summary of a multidisciplinary round-table discussion

F. Rojo, M. Preusser, J. Wolf, 2019, ESMO Open.

Enhancing tumor-targeting monoclonal antibodies therapy by PARP inhibitors

F. Rojo, J. Yélamos, J. Albanell, 2016, Oncoimmunology.

Pharmacodynamic Trial of Nimotuzumab in Unresectable Squamous Cell Carcinoma of the Head and Neck: A SENDO Foundation Study

S. Serrano, F. Rojo, J. Albanell, 2010, Clinical Cancer Research.

First-in-Human, Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of RO5126766, a First-in-Class Dual MEK/RAF Inhibitor in Patients with Solid Tumors

F. Rojo, J. Albanell, J. Soria, 2012, Clinical Cancer Research.

Cancer Therapy : Preclinical Targeting Epithelial-to-Mesenchymal Transition with Met Inhibitors Reverts Chemoresistance in Small Cell Lung Cancer

M. Salido, F. Rojo, J. Albanell, 2014 .

Randomized phase II study of fulvestrant plus palbociclib or placebo in endocrine-sensitive, hormone receptor-positive/HER2-advanced breast cancer: GEICAM/2014-12 (FLIPPER).

F. Rojo, J. Albanell, M. Margelí, 2021, European journal of cancer.

Circulating immune biomarkers in peripheral blood correlate with clinical outcomes in advanced breast cancer

F. Rojo, V. Sánchez-Margalet, R. Caballero, 2021, Scientific Reports.

Enhanced MAF Oncogene Expression and Breast Cancer Bone Metastasis

Evarist Planet, Ana Lluch, R. Gomis, 2015, Journal of the National Cancer Institute.

Presence of rare potential pathogenic variants in subjects under 65 years old with very severe or fatal COVID-19

Maximiliano García Torrejón, I. Mahillo, F. Rojo, 2022, Scientific Reports.

PP2A regulates signaling through hormonal receptors in breast cancer with important therapeutic implications.

F. Rojo, J. Madoz-Gúrpide, J. García-Foncillas, 2017, Biochimica et biophysica acta. Reviews on cancer.

Targeting PP2A to overcome enzalutamide resistance in AR+ breast tumors.

F. Rojo, J. García-Foncillas, M. Pedregal, 2017, Endocrine-related cancer.

PP2A inhibition as a novel therapeutic target in castration-resistant prostate cancer

F. Rojo, J. Madoz-Gúrpide, P. González-Alonso, 2015, Tumor Biology.

ADAMTS1 contributes to the acquisition of an endothelial-like phenotype in plastic tumor cells.

F. Rojo, A. Griffioen, S. Ramón y. Cajal, 2010, Cancer research.

Tumor and Stem Cell Biology Cancer Research ADAMTS 1 Contributes to the Acquisition of an Endothelial-like Phenotype in Plastic Tumor Cells

F. Rojo, A. Griffioen, S. Y. Cajal, 2010 .

Snail1 Expression Is Required for Sarcomagenesis12

F. Rojo, J. Albanell, A. Muñoz, 2014, Neoplasia.

Pharmacodynamic S tudies o f t he E pidermal G rowth F actor Receptor I nhibitor Z D1839 i n S kin F rom C ancer P atients: Histopathologic a nd M olecular C onsequences o f Receptor I nhibition

J. Baselga, R. Nicholson, R. Herbst, 2002 .

FGFR4 regulates tumor subtype differentiation in luminal breast cancer and metastatic disease.

Sara R. Selitsky, David L. Marron, C. Fan, 2020, The Journal of clinical investigation.

Update on Management Recommendations for Advanced Cutaneous Squamous Cell Carcinoma

F. Rojo, J. García-Foncillas, R. Mesía, 2022, Cancers.

Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER+) node-negative breast cancer.

F. Rojo, J. Albanell, A. Lluch, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone

J. Cuzick, W. Gradishar, M. Gnant, 2019, Breast Cancer Research and Treatment.

Targeting Epithelial-to-Mesenchymal Transition with Met Inhibitors Reverts Chemoresistance in Small Cell Lung Cancer

M. Salido, F. Rojo, J. Albanell, 2013, Clinical Cancer Research.

A Novel NFIX-STAT6 Gene Fusion in Solitary Fibrous Tumor: A Case Report

F. Rojo, C. Fletcher, J. Martín-Broto, 2021, International journal of molecular sciences.

Basement Membrane-Rich Organoids with Functional Human Blood Vessels Are Permissive Niches for Human Breast Cancer Metastasis

F. Rojo, S. Zazo, L. Álvarez-Vallina, 2013, PloS one.

Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology

F. Rojo, J. Albanell, M. Martín, 2017, Clinical and Translational Oncology.

Palbociclib Rechallenge for Hormone Receptor–Positive/HER-Negative Advanced Breast Cancer: Findings from the Phase II BioPER Trial

F. Rojo, L. Comerma, G. Curigliano, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

High Numbers of Circulating CD57+ NK Cells Associate with Resistance to HER2-Specific Therapeutic Antibodies in HER2+ Primary Breast Cancer

F. Rojo, L. Comerma, J. Albanell, 2019, Cancer Immunology Research.

NK Cell Infiltrates and HLA Class I Expression in Primary HER2+ Breast Cancer Predict and Uncouple Pathological Response and Disease-free Survival

A. Gonzalez-Perez, C. Rubio-Perez, D. Tamborero, 2018, Clinical Cancer Research.

Molecular evidence of field cancerization initiated by diabetes in colon cancer patients

F. Rojo, A. Sanz, A. Ortiz, 2019, Molecular oncology.

Deregulation of SET is Associated with Tumor Progression and Predicts Adverse Outcome in Patients with Early-Stage Colorectal Cancer

F. Rojo, J. Madoz-Gúrpide, S. Zazo, 2019, Journal of clinical medicine.

Analysis of Potential Alterations Affecting SETBP1 as a Novel Contributing Mechanism to Inhibit PP2A in Colorectal Cancer Patients

F. Rojo, J. Madoz-Gúrpide, C. Chamizo, 2018, World Journal of Surgery.

Three monocytic neoplasms in a single patient

M. Piris, F. Rojo, Nerea Carvajal, 2020, Leukemia & lymphoma.

Interplay between Natural Killer Cells and Anti-HER2 Antibodies: Perspectives for Breast Cancer Immunotherapy

F. Rojo, J. Albanell, S. Servitja, 2017, Front. Immunol..

Autocrine CCL5 Effect Mediates Trastuzumab Resistance by ERK Pathway Activation in HER2-Positive Breast Cancer

F. Rojo, J. Albanell, A. Lluch, 2020, Molecular Cancer Therapeutics.

Tumor-Associated Fibroblasts Promote HER2-Targeted Therapy Resistance through FGFR2 Activation

F. Rojo, J. Albanell, A. Lluch, 2019, Clinical Cancer Research.

Neoadjuvant Therapy with Weekly Nanoparticle Albumin-Bound Paclitaxel for Luminal Early Breast Cancer Patients: Results from the NABRAX Study (GEICAM/2011-02), a Multicenter, Non-Randomized, Phase II Trial, with a Companion Biomarker Analysis.

F. Rojo, E. Espinosa, J. Palacios, 2017, The oncologist.

Recurrent presence of the PLCG1 S345F mutation in nodal peripheral T-cell lymphomas

M. Piris, R. Franco, F. Rojo, 2015, Haematologica.

Cost-benefit analysis of ALK diagnosis vs. non-diagnosis in patients with advanced non–small cell lung cancer in Spain

F. Rojo, M. Majem, A. Ortega, 2022, Global & regional health technology assessment.

ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells.

J. Baselga, F. Rojo, J. Albanell, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM/2006-14 trial

F. Rojo, J. Albanell, A. Lluch, 2014, British Journal of Cancer.

[The use of targeted therapies in oncology and their impact in the design of clinical trials: epidermal growth factor receptors 1 and 2 as a paradigm].

F. Rojo, J. Albanell, A. Rovira, 2013, Medicina clinica.

DNA Methylation of miR-7 is a Mechanism Involved in Platinum Response through MAFG Overexpression in Cancer Cells

A. Dopazo, J. Benítez, F. Rojo, 2017, Theranostics.

MicroRNAs in Rectal Cancer: Functional Significance and Promising Therapeutic Value

F. Rojo, J. García-Foncillas, I. Cristóbal, 2020, Cancers.

The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group

Andrew H. Beck, Clare C. Yu, M. N. Vidya, 2021, npj Breast Cancer.

Angiopoietin-2 is a negative prognostic marker in small cell lung cancer.

F. Rojo, J. Albanell, O. Arpí, 2015, Lung cancer.

Thymidylate synthase expression as a predictive biomarker of pemetrexed sensitivity in advanced non-small cell lung cancer

Sandra Zazo, F. Rojo, J. Madoz-Gúrpide, 2015, BMC Pulmonary Medicine.

CIP2A as a Key Regulator for AKT Phosphorylation Has Partial Impact Determining Clinical Outcome in Breast Cancer

F. Rojo, J. Albanell, J. Madoz-Gúrpide, 2022, Journal of clinical medicine.

PP2A inhibition determines poor outcome and doxorubicin resistance in early breast cancer and its activation shows promising therapeutic effects

F. Rojo, J. Albanell, A. Lluch, 2015, Oncotarget.

miR-146a-5p Promotes Angiogenesis and Confers Trastuzumab Resistance in HER2+ Breast Cancer

F. Rojo, J. Albanell, A. Lluch, 2023, Cancers.

Functional and Clinical Impact of CircRNAs in Oral Cancer

F. Rojo, J. Madoz-Gúrpide, J. García-Foncillas, 2020, Cancers.

Activation of MET pathway predicts poor outcome to cetuximab in patients with recurrent or metastatic head and neck cancer

F. Rojo, J. Madoz-Gúrpide, S. Zazo, 2015, Journal of Translational Medicine.

MicroRNA-199b Deregulation Shows Oncogenic Properties and Promising Clinical Value as Circulating Marker in Locally Advanced Rectal Cancer Patients

F. Rojo, J. Madoz-Gúrpide, J. García-Foncillas, 2022, International journal of molecular sciences.

[Multidisciplinary consensus on optimizing the detection of NTRK gene alterations in tumours].

F. López-Ríos, F. Rojo, E. de Álava, 2021, Revista espanola de patologia : publicacion oficial de la Sociedad Espanola de Anatomia Patologica y de la Sociedad Espanola de Citologia.

Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Non-Small Cell Lung Carcinoma Patients: the ROSING Study.

J. Mate, M. Salido, F. López-Ríos, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

PI3KCA mutations in advanced urothelial carcinoma: A potential therapeutic target?

M. Loda, P. Kantoff, S. Signoretti, 2012 .

Distinct GSDMB protein isoforms and protease cleavage processes differentially control pyroptotic cell death and mitochondrial damage in cancer cells

F. Rojo, J. Albanell, A. Lluch, 2022, bioRxiv.

c-Jun N-Terminal Kinase Inactivation by Mitogen-Activated Protein Kinase Phosphatase 1 Determines Resistance to Taxanes and Anthracyclines in Breast Cancer

F. Rojo, J. Albanell, A. Lluch, 2016, Molecular Cancer Therapeutics.

High Interobserver Variability among Pathologists Using Combined Positive Score to Evaluate PD-L1 Expression in Gastric, Gastroesophageal Junction and Esophageal Adenocarcinoma.

Laura H. Tang, F. Rojo, J. Rüschoff, 2023, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

High circulating hepatocyte growth factor levels associate with epithelial to mesenchymal transition and poor outcome in small cell lung cancer patients

F. Rojo, J. Albanell, O. Arpí, 2014, Oncotarget.

MicroRNA-21 predicts response to preoperative chemoradiotherapy in locally advanced rectal cancer

F. Rojo, J. García-Foncillas, C. Caramés, 2015, International Journal of Colorectal Disease.

Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials

Jacqueline A. Hall, Sarah N. Dudgeon, A. Gown, 2020, npj Breast Cancer.

High VEGFR3 Expression Reduces Doxorubicin Efficacy in Triple-Negative Breast Cancer

F. Rojo, A. Lluch, J. Madoz-Gúrpide, 2023, International journal of molecular sciences.

Comparison of Molecular Analysis and Histopathology for Axillary Lymph Node Staging in Primary Breast Cancer: Results of the B-CLOSER-I Study

F. Rojo, A. Velasco, D. Hardisson, 2012, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

Age-dependent association of clonal hematopoiesis with COVID-19 mortality in patients over 60 years

F. Rojo, S. Zazo, M. Cortón, 2022, GeroScience.

The PI3-K/AKT/mTOR pathway as a target for breast cancer therapy

J. Baselga, F. Rojo, S. Cosimo, 2007 .

Should we also evaluate SET together with CIP2A for the treatment with second-generation tyrosine kinase inhibitors in chronic myeloid leukemia?

F. Rojo, P. González-Alonso, J. García-Foncillas, 2015, Leukemia.

PP2A Inhibition Is a Common Event in Colorectal Cancer and Its Restoration Using FTY720 Shows Promising Therapeutic Potential

Sandra Zazo, F. Rojo, J. Madoz-Gúrpide, 2014, Molecular Cancer Therapeutics.

Activation of the Tumor Suppressor PP2A Emerges as a Potential Therapeutic Strategy for Treating Prostate Cancer

F. Rojo, J. Madoz-Gúrpide, P. González-Alonso, 2015, Marine drugs.

Dose-dependent inhibition of the EGFR and signalling pathways with the anti-EGFR monoclonal antibody (MAb) EMD 72000 administered every three weeks (q3w). A phase I pharmacokinetic/pharmacodynamic (PK/PD) study to define the optimal biological dose (OBD).

J. Baselga, R. Salazar, F. Rojo, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I study of humanized IgG1 anti-epidermal growth factor receptor (EGFR) monoclonal antibody EMD 72000 plus gemcitabine (Gem) in advanced pancreatic cancer.

J. Baselga, F. Rojo, W. Schmiegel, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pyrosequencing-Based Assays for Rapid Detection of HER2 and HER3 Mutations in Clinical Samples Uncover an E332E Mutation Affecting HER3 in Retroperitoneal Leiomyosarcoma

F. Rojo, J. Madoz-Gúrpide, S. Zazo, 2015, International journal of molecular sciences.

mTOR inhibition and trastuzumab-emtansine (T-DM1) in HER2-positive breast cancer.

F. Rojo, J. Albanell, A. Lluch, 2022, Molecular cancer research : MCR.

Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancer

F. Rojo, J. Albanell, S. González, 2017, Oncotarget.

Apocrine carcinoma of the anogenital region. A case report including immunohistochemical and molecular study, discussion of differential diagnosis and a review of the literature

S. Cajal, F. Rojo, P. Huguet, 2006, International Journal of Colorectal Disease.

Validation and clinical application of a targeted next-generation sequencing gene panel for solid and hematologic malignancies

F. Rojo, S. Zazo, C. Chamizo, 2020, PeerJ.

Real-world biomarker testing rate and positivity rate in NSCLC in Spain: Prospective Central Lung Cancer Biomarker Testing Registry (LungPath) from the Spanish Society of Pathology (SEAP)

Javier M. Martín-López, F. Rojo, C. Salas, 2021, Journal of Clinical Pathology.

ALK chromosomal alterations in colon cancer patients.

F. Solé, M. Salido, F. Rojo, 2010 .

Nuclear NF-kb/p65 expression and response to neoadjuvant chemotherapy in breast cancer.

Robin L. Jones, M. Dowsett, J. Reis-Filho, 2010 .

Deregulation of miR‐200b, miR‐200c and miR‐429 indicates its potential relevant role in patients with colorectal cancer liver metastasis

F. Rojo, J. Madoz-Gúrpide, J. García-Foncillas, 2014, Journal of surgical oncology.

Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group.

Sarah N. Dudgeon, A. Beck, T. Nielsen, 2020, NPJ breast cancer.

Gene Expression Profiling in True Interval Breast Cancer Reveals Overactivation of the mTOR Signaling Pathway

X. Castells, F. Rojo, J. Albanell, 2013, Cancer Epidemiology, Biomarkers & Prevention.

Clinical Usefulness of 5-FU Metabolic Enzymes as Predictive Markers of Response to Chemotherapy in Colorectal Cancer

F. Rojo, J. Madoz-Gúrpide, P. González-Alonso, 2016, World Journal of Surgery.

Up-regulation of c-Cbl suggests its potential role as oncogene in primary colorectal cancer

F. Rojo, J. Madoz-Gúrpide, J. García-Foncillas, 2014, International Journal of Colorectal Disease.

Publisher Correction: Circulating immune biomarkers in peripheral blood correlate with clinical outcomes in advanced breast cancer

F. Rojo, V. Sánchez-Margalet, R. Caballero, 2021, Scientific Reports.

Nuclear DICKKOPF-1 as a biomarker of chemoresistance and poor clinical outcome in colorectal cancer

M. Fraga, D. Pisano, C. López-Otín, 2015, Oncotarget.

Comment on ‘MicroRNA-199b-5p attenuates TGF-β1-induced epithelial–mesenchymal transition in hepatocellular carcinoma’

F. Rojo, J. García-Foncillas, I. Cristóbal, 2018, British Journal of Cancer.

FISH and immunohistochemical status of the hepatocyte growth factor receptor (c-Met) in 184 invasive breast tumors

S. Serrano, F. Solé, M. Salido, 2009, Breast Cancer Research.

A phase I study of the SRC kinase inhibitor dasatinib with trastuzumab and paclitaxel as first line therapy for patients with HER2-overexpressing advanced breast cancer. GEICAM/2010-04 study

F. Rojo, A. Pandiella, A. Urruticoechea, 2017, Oncotarget.

Downregulation of miR-138 as a Contributing Mechanism to Lcn-2 Overexpression in Colorectal Cancer with Liver Metastasis

F. Rojo, P. González-Alonso, J. García-Foncillas, 2016, World Journal of Surgery.

Diabetes‐mediated promotion of colon mucosa carcinogenesis is associated with mitochondrial dysfunction

F. Rojo, A. Sanz, A. Ortiz, 2019, Molecular oncology.

The miRNA-449 family mediates doxorubicin resistance in triple-negative breast cancer by regulating cell cycle factors

F. Rojo, J. Albanell, A. Lluch, 2019, Scientific Reports.

a Specific Epidermal Growth Factor Receptor ( EGFR ) Tyrosine Kinase Inhibitor , Induces the Formation of Inactive EGFR / HER 2 and EGFR / HER 3 Heterodimers and Prevents Heregulin Signaling in HER 2-overexpressing Breast Cancer Cells 1

J. Baselga, F. Rojo, J. Albanell, 2003 .

ESMO Expert Consensus Statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer.

E. Provenzano, L. Carey, A. Vincent-Salomon, 2023, Annals of oncology : official journal of the European Society for Medical Oncology.

The best manuscript: Pharmacodynamic studies of gefitinib in tumor biopsy specimens from patients with advanced gastric carcinoma[含解説者コメント]

F. Rojo, J. Albanell, J. Tabernero, 2006 .

Pharmacodynamics: biological activity of targeted therapies in clinical trials

F. Rojo, J. Albanell, J. Corominas, 2007, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

PP2A plays a key role in inflammation and cancer through tristetraprolin activation

F. Rojo, J. Madoz-Gúrpide, J. García-Foncillas, 2016, Annals of the rheumatic diseases.

CIP2A confirms its prognostic value in triple-negative breast cancer

F. Rojo, J. Albanell, A. Lluch, 2017, Oncogene.

P1.09-09 Evaluation of a Novel ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in NSCLC Patients

M. Salido, F. López-Ríos, F. Rojo, 2018, Journal of Thoracic Oncology.

Role of SALL4 in HER2+ Breast Cancer Progression: Regulating PI3K/AKT Pathway

F. Rojo, J. Albanell, S. Zazo, 2022, International journal of molecular sciences.

Expression of Phosphorylated BRD4 Is Markedly Associated with the Activation Status of the PP2A Pathway and Shows a Strong Prognostic Value in Triple Negative Breast Cancer Patients

C. Chiang, F. Rojo, J. Albanell, 2021, Cancers.

Deregulation of the miR-19b/PPP2R5E Signaling Axis Shows High Functional Impact in Colorectal Cancer Cells

F. Rojo, J. Madoz-Gúrpide, J. García-Foncillas, 2023, International journal of molecular sciences.

Comment on “miR-199b-5p-DDR1-ERK signalling axis suppresses prostate cancer metastasis via inhibiting epithelial-mesenchymal transition”

F. Rojo, J. García-Foncillas, I. Cristóbal, 2021, British Journal of Cancer.

MicroRNA-199b Deregulation Shows a Strong SET-Independent Prognostic Value in Early-Stage Colorectal Cancer

F. Rojo, J. Madoz-Gúrpide, S. Zazo, 2020, Journal of clinical medicine.

Clinical significance of miR‐126 in colorectal cancer

F. Rojo, J. Madoz-Gúrpide, S. Zazo, 2014, Genes, chromosomes & cancer.

A phase Ib study of sonidegib (LDE225), an oral small molecule inhibitor of smoothened or Hedgehog pathway, in combination with docetaxel in triple negative advanced breast cancer patients: GEICAM/2012–12 (EDALINE) study

H. Colom, F. Rojo, A. Urruticoechea, 2018, Investigational New Drugs.

The Hippo Pathway Transducers YAP1/TEAD Induce Acquired Resistance to Trastuzumab in HER2-Positive Breast Cancer

F. Rojo, J. Albanell, A. Lluch, 2020, Cancers.

Gene Expression Pro fi ling in True Interval Breast Cancer Reveals Overactivation of the mTOR Signaling Pathway

X. Castells, F. Rojo, J. Albanell, 2014 .

High Proliferation Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Early Breast Cancer.

F. Rojo, J. Albanell, A. Ruíz, 2016, The oncologist.

GWAS and meta-analysis identifies 49 genetic variants underlying critical COVID-19

Matthew A. Wiles, Ellen C. Smith, Jack D. Sanders, 2023, Nature.

The miRNA-449 family mediates doxorubicin resistance in triple-negative breast cancer by regulating cell cycle factors

F. Rojo, J. Albanell, A. Lluch, 2019, Scientific Reports.

Shallow whole genome sequencing for robust copy number profiling of formalin-fixed paraffin-embedded breast cancers

Harry W. Clifford, S. Chin, C. Caldas, 2017, bioRxiv.

PP2A inhibition determines poor outcome and doxorubicin resistance in early breast cancer and its activation shows promising therapeutic effects

F. Rojo, J. Albanell, A. Lluch, 2015, OncoTarget.

Schedule-dependent effects of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib in combination with the mammalian target of rapamycin (mTOR) inhibitor everolimus (RAD001).

J. Baselga, F. Rojo, J. Arribas, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Therapeutic implications of the PP2A/MET signalling axis in doxorubicin‐induced cardiotoxicity and antitumour properties

F. Rojo, J. García-Foncillas, I. Cristóbal, 2020, British journal of pharmacology.

The SMAD3‐induced effects in colorectal cancer are orchestrated by a complex network of long noncoding RNAs

F. Rojo, J. García-Foncillas, I. Cristóbal, 2022, Journal of cellular physiology.

Pharmacodynamics: biological activity of targeted therapies in clinical trials

F. Rojo, J. Albanell, J. Corominas, 2007, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer

A. Cebrián, C. Nadal, F. Rojo, 2019, Scientific Reports.

Potential Therapeutic Impact of miR-145 Deregulation in Colorectal Cancer.

F. Rojo, J. García-Foncillas, I. Cristóbal, 2018, Molecular therapy : the journal of the American Society of Gene Therapy.

Targeting stromal remodeling and cancer stem cell plasticity to overcome chemoresistance in triple negative breast cancer

F. Rojo, S. O'toole, P. Timpson, 2017, bioRxiv.

Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer.

P. Pandolfi, L. Salmena, J. Teruya-Feldstein, 2008, The Journal of clinical investigation.

Targeting stromal remodeling and cancer stem cell plasticity overcomes chemoresistance in triple negative breast cancer

F. Rojo, S. O'toole, P. Timpson, 2018, Nature Communications.

High TGFbeta-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene.

J. Mora, J. Baselga, F. Rojo, 2007, Cancer cell.